Vol 48 No 2

Novel thulium laser fiber appears to outperform Holmium:YAG laser

January 27, 2020

A new tool for kidney stone ablation demonstrates strong potential to dust and fragment stones more quickly and efficiently than devices currently available in the United States. However, clinical studies must be performed before this technology can be used during lithotripsy nationally.

Drug-coated balloon found efficacious for strictures

January 28, 2020

“If the long-term results prove to be as positive as the short-term results, then this could provide an intermediate option for patients with recurrent bulbar urethral strictures," says Sean P. Elliott, MD, MS.

PAE safe, durable for retention, hematuria in non-index BPH patients

January 28, 2020

Prostatic artery embolization offers a safe and durably effective treatment for urinary retention and gross hematuria in challenging non-index BPH patients, according to the results of a retrospective study published in Urology (Nov. 14, 2019 [Epub ahead of print]).

Trial supports combined behavioral, medical approach to treating OAB

January 29, 2020

Results of a randomized controlled clinical trial provide a rationale for urologists to integrate behavioral treatments into their practice for managing men with lower urinary tract symptoms of overactive bladder, according to the study’s authors.

Risk of chronic opioid use low after RP

January 29, 2020

Chronic opioid use is rare following radical prostatectomy in Europe. Slightly more than half of men undergoing RP in Sweden between 2007 and 2017 were found to have filled an opioid prescription, but the proportion who became chronic opioid users was less than 1%.

PSMA-targeted therapy well tolerated in men with mCRPC

January 30, 2020

A radiolabeled small molecule that binds to prostate-specific membrane antigen is continuing to show promise for treating progressive metastatic castrate-resistant prostate cancer, according to researchers at the University of California, Los Angeles.

What are Category III codes, and how are they best used for billing?

January 31, 2020

"Category III codes are designated as temporary codes by the AMA. Even though the codes are considered temporary, they are an integral and important part of the system," write Jonathan Rubenstein, MD, and Mark Painter.

TP-Bx: The answer to rising infectious complications?

February 03, 2020

"A more standardized protocol that is office based, reliable, and reproducible as well as cost- and time-efficient is required to entice more urologists to abandon the TRUS-BX approach," writes J. Brantley Thrasher, MD.

Bladder Ca: Genetic testing, targeted therapies signal a new era of precision medicine

February 05, 2020

“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” according to Richard Pazdur, MD.

Bladder cancer biomarker test accurately adjudicates atypical cytology

February 05, 2020

“The results of our retrospective study support taking advantage of the Cxbladder test to identify patients who should be further evaluated for cancer and to spare those who likely do not have cancer from an unnecessary workup," says Badrinath Konety, MD, MBA.